VEGFA and inflammatory response: Administration of BIBF1000, an orally active small molecule triple-tyrosine kinase inhibitor that targets VEGF, PDGF, and FGF receptor signaling, significantly reduced allergen-induced chronic airway inflammation, mucus expression, airway, and pulmonary arterial remodeling.